Featured Publications
Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American children
2021
Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.
Yee ME, Lai KW, Bakshi N, Grossman JK, Jaggi P, Mallis A, Wang YF, Jerris RC, Lane PA, Yildirim I. Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019. Pediatrics 2021, 149 PMID: 34913059, PMCID: PMC8959248, DOI: 10.1542/peds.2021-051892.Peer-Reviewed Original ResearchConceptsSickle cell diseaseBloodstream infectionsBlood culturesSickle cell anemia genotypesRetrospective cohort studyInvasive bacterial infectionsMultivariate logistic regressionConfidence intervalsAverage incidence rateSpectrum of pathogensAntibiotic prophylaxisEligible patientsFunctional aspleniaBSI episodesCohort studyChronic transfusionMedian ageAnnual incidenceOverall incidenceRisk factorsIncidence rateCell diseaseEmpirical treatmentBordetella holmesiiCommon pathogensPopulation-Based Surveillance of Pneumococcal Infections in Children with Sickle Cell Disease before and after Prevnar 7® and Prevnar 13® Licensure: Implications for Expanded Vaccination
Adamkiewicz T, Thomas S, Tunali A, Lai K, Yee M, Yildirim I, Lane P, Omole F, Farley M. Population-Based Surveillance of Pneumococcal Infections in Children with Sickle Cell Disease before and after Prevnar 7® and Prevnar 13® Licensure: Implications for Expanded Vaccination. Blood 2021, 138: 763. DOI: 10.1182/blood-2021-154474.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseSickle cell diseaseIPD ratesPCV periodPCV7 licensureMean ageRelative riskCell diseaseGeneral populationNew vaccinesNon-PCV13 serotypesPneumococcal polysaccharide vaccineRegistry of patientsPopulation-based surveillanceProphylactic antibiotic useEmory University Institutional Review BoardAntibiotic susceptibility testingInstitutional review boardUniversity Institutional Review BoardAge of infectionIPD diagnosisPCV eraPCV13 periodPCV13 serotypesPCV7 period
2020
The burden of respiratory syncytial virus infections among children with sickle cell disease
Rostad CA, Maillis AN, Lai K, Bakshi N, Jerris RC, Lane PA, Yee ME, Yildirim I. The burden of respiratory syncytial virus infections among children with sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28759. PMID: 33034160, PMCID: PMC8246443, DOI: 10.1002/pbc.28759.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSickle cell diseaseRespiratory viral panelRSV-positive casesRSV infectionAnnual incidenceHospitalization ratesCell diseaseBurden of RSVPediatric lower respiratory tract infectionsLaboratory-confirmed RSV infectionRespiratory syncytial virus infectionRSV-related hospitalization rateLower respiratory tract infectionsRSV positive testRSV-negative childrenRSV-negative patientsAcute chest syndromeSyncytial virus infectionRespiratory tract infectionsAverage annual incidenceMultivariate logistic regressionConfidence intervalsCase-control studyOutcome of childrenMicrobiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease
Kao CM, Yee ME, Maillis A, Lai K, Bakshi N, Rostad BS, Jerris RC, Lane PA, Yildirim I. Microbiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease. Pediatric Blood & Cancer 2020, 67: e28517. PMID: 32710705, PMCID: PMC8369475, DOI: 10.1002/pbc.28517.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMethicillin-susceptible Staphylococcus aureusMagnetic resonance imagingAntibiotic treatmentOperative culturesCell diseaseLarge tertiary pediatric centerPrescribed antibiotic treatmentTertiary pediatric centerCulture-positive casesKey presenting symptomsChildren ages 6Bone painMicrobiologic etiologyPresenting symptomPediatric centersBone infarctsMedical chartsMicrobiologic findingsRadiographic featuresImaging featuresOsteomyelitisProbable osteomyelitisDiagnostic codingTissue debridementInfluenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017
Kao CM, Lai K, McAteer JM, Elmontser M, Quincer EM, Yee MEM, Tippet A, Jerris RC, Lane PA, Anderson EJ, Bakshi N, Yildirim I. Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012‐2017. Pediatric Blood & Cancer 2020, 67: e28358. PMID: 32469138, PMCID: PMC8221251, DOI: 10.1002/pbc.28358.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessSickle cell diseaseVaccine effectivenessYears of ageInfluenza infectionOdds ratioCell diseaseLaboratory-confirmed influenza infectionSeasonal influenza vaccine effectivenessTest-negative case-control study designAdjusted vaccine effectivenessAdjusted VE estimatesInfluenza-positive casesOverall vaccine effectivenessAcute chest syndromeBurden of influenzaPatients 6 monthsMulticenter prospective studyTest-negative controlsAnnual influenza vaccineCase-control study designConfidence intervalsLogistic regression modelsChest syndromeInfluenza season
2019
Incidence of invasive Haemophilus influenzae infections in children with sickle cell disease
Yee ME, Bakshi N, Graciaa SH, Lane PA, Jerris RC, Wang YF, Yildirim I. Incidence of invasive Haemophilus influenzae infections in children with sickle cell disease. Pediatric Blood & Cancer 2019, 66: e27642. PMID: 30724001, PMCID: PMC6472970, DOI: 10.1002/pbc.27642.Peer-Reviewed Original ResearchConceptsSickle cell diseaseComprehensive clinical databaseInfluenzae infectionAntibiotic prophylaxisInfluenzae diseaseInvasive infectionsCell diseaseInvasive Haemophilus influenzae infectionsPediatric tertiary care centerHaemophilus influenzae type bLarge pediatric tertiary care centerUniversal antibiotic prophylaxisSterile body fluid culturesTertiary care centerHaemophilus influenzae infectionsBody fluid culturesInfluenzae type bYears of ageDistribution of serotypesNonvaccine serotypesClinical featuresOverall incidenceCare centerFluid cultureIncidence rate
2018
1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
Yildirim I, Little B, Shea K, Pelton S, Massachusetts M. 1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease. Open Forum Infectious Diseases 2018, 5: s441-s442. PMCID: PMC6253418, DOI: 10.1093/ofid/ofy210.1261.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseStreptococcus pneumoniaeIPD casesPneumococcal diseaseVaccine serotypesIncidence of IPDCommon clinical presentationIntroduction of PCV13Pneumococcal conjugate vaccineOverall mortality rateChildhood immunization scheduleSickle cell diseaseYears of ageEnhanced surveillance systemIPD incidenceCommon comorbiditiesConjugate vaccineMassachusetts childrenClinical presentationImmunization scheduleCurrent epidemiologyCNS diseaseHematologic malignanciesCell diseaseClinical data